Qrons Inc., a biotechnology company focused on combating neuronal and infectious diseases, has recently welcomed Professor Shiri Navon-Venezia to its Scientific Advisory Board. The esteemed Professor, known for her expertise in microbiology and antibiotic resistance, is expected to play a pivotal role in shaping Qrons’ research program to address the global public health threat of antimicrobial resistance.
With antimicrobial resistance causing at least 1.27 million deaths worldwide in 2019, according to a report in The Lancet, finding innovative solutions is of paramount importance. Professor Navon-Venezia’s background in antibiotic research will prove invaluable as Qrons explores the therapeutic potential of Tellurium-based compounds in combating antibiotic-resistant bacterial infections like sepsis.
Sepsis, a life-threatening medical emergency, claims hundreds of thousands of lives each year in the United States alone. The Centers for Disease Control and Prevention (CDC) reports that more than 1.7 million people develop sepsis annually, with a staggering 1 in 3 hospital deaths being attributed to this condition. Qrons aims to tackle this pressing issue by leveraging Professor Navon-Venezia’s expertise to develop effective treatment options.
Qrons, headquartered in New York City with research centered in Israel, is committed to collaborating with universities, scientists, and companies engaged in cutting-edge research in stem cells, antibiotic-resistant drug development, and tissue engineering. By forging strategic partnerships, Qrons aims to harness unique knowledge and intellectual properties to combat neuronal and infectious diseases.
The addition of Professor Navon-Venezia to Qrons’ Scientific Advisory Board marks an important milestone in the company’s journey toward developing groundbreaking treatments. With her distinguished career, extensive research contributions, and wealth of expertise, Professor Navon-Venezia’s insights will undoubtedly guide Qrons in their mission to make a significant impact on the field of sepsis research.
FAQ
What is antimicrobial resistance?
Antimicrobial resistance refers to the ability of microorganisms (such as bacteria, viruses, fungi, and parasites) to withstand the effects of drugs that were previously effective in killing them or inhibiting their growth.
What is sepsis?
Sepsis is a life-threatening condition caused by the body’s extreme response to an infection. It can lead to tissue damage, organ failure, and death if not treated promptly.
What is Qrons Inc.?
Qrons Inc. is a biotechnology company focused on developing innovative products, treatments, and technologies to combat neuronal and infectious diseases. With a specific emphasis on antibiotic-resistant bacteria, Qrons aims to address the growing global health challenge of antimicrobial resistance.
How many people develop sepsis each year in the U.S.?
According to the Centers for Disease Control and Prevention (CDC), more than 1.7 million people develop sepsis annually in the United States.